NIH Has a $47.2 Billion Budget and Is Making 66% Fewer Grants: Inside the 2026 Grantmaking Slowdown and What Researchers Should Actually Do About It

Here is the paradox at the center of American biomedical research in 2026: the National Institutes of Health has roughly the same amount of money it had last year, and it is funding far fewer scientists. Congress appropriated $47.2 billion to NIH for fiscal 2026 — essentially flat, not a cut. And yet, by the end of February, the agency had issued 66% fewer competitive grant awards than its average for the same period across fiscal years 2021 through 2024, according to reporting compiled by the Association of American Universities. The monetary value of awards was down 54% against that same baseline. As of late May, NIH grant awards were still running roughly 48% below historical norms.

A budget that holds steady while grantmaking collapses is not a funding story. It is a plumbing story. The money exists; it is not reaching laboratories. For any researcher, department administrator, or research-dependent nonprofit, understanding why the pipeline seized up is the difference between waiting for a thaw that may not come on your timeline and building a funding strategy that survives it.

The numbers, and why they're worse than a headline cut

Consider what a flat budget with a two-thirds drop in awards actually implies. The dollars appropriated by Congress do not disappear — they either get obligated later in the fiscal year in a compressed rush, get concentrated into fewer and larger multi-year commitments, or sit unobligated. Reporting through the spring pointed to all three dynamics at once.

The success-rate data tells the human side. In FY25, only 17% of applicants received awards — the lowest success rate in 30 years. For early-stage investigators, the picture was starker still: their success rate fell to 18.5%, down from 29.8% in FY23. That is nearly a halving of the odds for exactly the cohort — new faculty, first-time principal investigators — whose careers are most fragile and most dependent on that first R01 landing on schedule. A postdoc weighing whether to stay in academia reads those numbers as a verdict.

The award-volume figures from FY26 make clear the trend didn't reverse. Separate reporting placed NIH at 1,385 competitive grants awarded as of late March, down 54% from the 3,024 awarded during the same window in FY25. The specific percentages vary by snapshot and methodology — some analyses cite figures as steep as 74% below the multi-year average at certain dates — but every credible source points the same direction: a dramatic, sustained reduction in the rate at which NIH is putting money into new research.

Why the money isn't moving

The slowdown is the product of several compounding failures rather than a single decision. Reporting identifies a convergence of administrative disruption and structural policy change.

Administrative and operational disruption:

• Funds were held. OMB held appropriated NIH funds until March 16, 2026, delaying the agency's ability to obligate money early in the fiscal year.
• The workforce shrank. NIH lost nearly 20% of its workforce — more than 4,000 employees. Grant administration is labor-intensive; program officers, grants-management specialists, and review staff are the machinery that turns appropriations into awards. Remove a fifth of that machinery and throughput falls even if the money is there.
• A shutdown compounded the backlog. The October–November 2025 government shutdown added delay, and canceled advisory council meetings created a backlog of applications that could not be acted upon — because, by statute, most awards require council concurrence.

Structural and policy change:

• NOFOs collapsed. This is the single most telling data point. Only 14 Notices of Funding Opportunity were published by March 15, 2026, versus 756 in all of 2024. NOFOs are the doors through which applications enter; if the doors aren't opened, applications can't be submitted, and awards can't follow 12 to 18 months later. The 2026 NOFO drought is a leading indicator of a 2027 award drought.
• Political sign-off was added. New requirements route NOFOs through political-appointee approval before publication — a step that did not previously gate routine funding announcements and that structurally slows the pace at which opportunities reach researchers.
• Funding is concentrating. The agency has leaned toward multi-year funding concentration — committing to fewer recipients with larger, longer awards. That reduces the number of "shots on goal" the research enterprise gets each year.

Put together, this is not a temporary cash-flow hiccup. It is a re-engineering of how, and how quickly, NIH distributes money — and it sits inside a broader 2026 federal grants environment defined by the OMB Uniform Guidance overhaul, which expands agency discretion to terminate and reprioritize awards. Researchers should read the NIH slowdown and the Uniform Guidance changes as two expressions of the same shift toward tighter, more discretionary federal control over research dollars.

What this actually means for labs

The downstream consequences are already visible: labs facing permanent closures, training grants stalled, and early-career researchers openly alarmed about their prospects. Fewer awards means fewer trainees supported, which means a thinner pipeline of scientists five years out — a cost that doesn't show up in a budget table but compounds over a generation.

For a principal investigator, the strategic error would be to treat this as weather — something to wait out. The prudent posture is to treat it as climate, and to diversify accordingly. Three moves matter most over the next 18 months.

1. Widen the federal aperture beyond NIH. Biomedical and health-adjacent research has more than one federal patron. The NSF restarted its SBIR/STTR programs with a $250 million FY26 allocation and new tiers for deep-tech and instrumentation — a channel available to health-technology startups and academic spinouts. Mission agencies fund health-relevant work too: the Department of Defense's medical research programs, ARPA-H's health-breakthrough portfolio, and DOE's biological and computational programs all touch problems NIH-funded labs care about. A researcher whose work maps onto more than one agency's mission should be writing to more than one agency. See our analysis of the NSF SBIR/STTR relaunch for one active door.

2. Court private and philanthropic funders now, not later. Disease-focused foundations, patient-advocacy organizations, and large private funders move on faster cycles than NIH and are not subject to the same NOFO bottleneck. In a year when federal review timelines are unpredictable, a bridge grant from a foundation can keep a lab staffed and a project alive between federal windows. The philanthropic sector has visibly stepped toward research and community innovation in 2026, and PIs who have never written a foundation letter of inquiry should learn to.

3. Track NOFOs obsessively and apply the instant a door opens. Because the constraint is the number of open opportunities, the researchers who win in 2026–2027 will be the ones positioned to submit immediately when a relevant NOFO finally publishes. That means keeping specific aims warm, biosketches current, and institutional sign-offs pre-cleared — so that a 14-NOFO year doesn't become a zero-application year for your lab. When opportunities are scarce, readiness is the entire game.

The bottom line

NIH is not out of money. It is, for now, out of throughput — and the 2026 NOFO drought all but guarantees the award slowdown extends into 2027 regardless of what the topline budget says. For researchers, the correct response is neither panic nor patience. It is diversification: more agencies, more funder types, and a permanent state of application-readiness so that when the pipeline moves — in fits and starts — your proposals are already in the queue. The labs that treat the $47.2 billion paradox as a structural reality rather than a passing storm are the ones that will still be running experiments in 2028.

Granted helps researchers and research-driven organizations find every funding source they qualify for — federal, state, and private — not just the one agency they've always relied on. Start a free search to map your full funding landscape.